18th International Symposium on Translational Research in Oncology (TRANSONC)

 DRAFT PROGRAMME
Wednesday, 24th September 2025 Lansdowne Suite, Herbert Park Hotel 

Registration from 08:30                         RCPI 4 external CPD credits

Wednesday, 24thSeptember 2025, Lansdowne Suite, Herbert Park Hotel

      Registration from 08:30                                                        TBC: RCPI external CPD credits

09:00 – 09:15     Welcome and Introduction – Prof John Crown, St. Vincent’s Hospital, Dublin

SESSIOn 1:      Session Chair – Prof. Sara Hurvitz, Fred Hutch Cancer Center

09:15 – 09:45       Topic: ctDNA technology (ongoing studies, controversies in its use in routine practice for cancer

Dr. Heather Parsons, Dana-Farber Cancer Institute

09:45 – 10:15       Topic: Epigenetic modifiers

Dr. Karen Chichowski, Harvard Medical School

10:15 – 10:45       Topic: Disseminated Tumour Cells and the tumour microenvironment

Dr. Cyrus Gajar, Fred Hutch Cancer Center

10:45 – 11:00       Coffee break

SESSIOn 2:      Session Chair – Prof. Sara Hurvitz, Fred Hutch Cancer Center

11:00 – 11:30       Topic: Vepdegestrant

                                Dr. Janaki Parameswaran, Senior Medical Director, Arvinas

11:30 – 12:00       Topic: Atirmociclib

Pfizer

12:00 – 12:30        Topic: TBC

Speaker TBC

12:30 – 13:30 Lunch

SESSIOn 3:      Session Chair – Prof. John Crown, St Vincent’s Hospital; DCU; UCD

13:30 – 14:00        Topic: Novel targeted therapies

Dr. Neil O’Brien, David Geffen School of Medicine, UCLA

14:00 – 14:30       Topic: Novel targeted therapies

Dr. Martina McDermott, David Geffen School of Medicine, UCLA

KEYNOTE PRESENTATION

14:30 – 15:15        Topic TBC

Dr. Dennis J. Slamon, 2019 Lasker Award Winner, Director of Clinical/Translational Research, Director of the Revlon/UCLA Women’s Cancer Research Program at JCCC. Professor of Medicine, Chief, Division of Hematology/Oncology.

15:15 –   15:30     Coffee break

SESSIOn 4:      Session Chair – Prof. John Crown, St Vincent’s Hospital; DCU; UCD

15:30 – 16:00        Topic: Hapatobiliary Cancer

Dr. Grainne O’Kane, Pat Smullen Chair in Pancreatic Cancer, University College Dublin

16:00 – 16:30       Topic: Lung cancer

Dr. Patrick Forde, Trinity St. James’ Cancer Institute, Dublin

16:30-17:00         Topic: IO toxicity

 Dr. Jarushka Naidoo, Beaumont Hospital & Royal College of Surgeons in Ireland.

Thursday, 25th September 2025 Lansdowne Suite, Herbert Park Hotel

Registration from 08:30                                                             TBC: RCPI external CPD credits

ARTIFICIAL INTELLIGENCE IN MEDICINE

Session Chair – Prof. Mark Pegram, Stanford University School of Medicine

09:00 – 09:30        Topic: Targeting mutant ESR1

Speaker TBC

09:30 – 10:00        Topic: Inavolisib in PI3K mutant ER+ breast cancer

Speaker TBC

10:00 – 10:30        Topic: CID-078 – cyclin A/B, RxL inhibitor

 Circle Pharma

10:30 – 10: 45       Coffee break

SESSION 2: Session Chair – Prof. Mark Pegram, Stanford University School of Medicine

10:45 – 11:15        Topic: Artificial Intelligence (AI) in Pathology

Dr Donal O’Shea, CEO, Deciphex

11.15 – 11:45       Topic: Radiomics Artificial Intelligence

Dr Hiruka Itakura, Stanford University School of Medicine

11.45 – 12:15       Topic: AI in Pathology

 Prof. Hamid Tizhoosh, Department of Artificial Intelligence and Informatics, Mayo Clinic 

 12:15 – 13:15      Lunch

WHAT CAN WE LEARN FROM SPATIAL PROFILING OF TUMOUR TISSUES

Session Chair – Prof. Lajos Pusztai, Yale School of Medicine

13:15 – 13:45       Topic: GeoMx spatial transcriptomic technology

 Nanostring

13:45 – 14:15       Mixed molecular subtypes in ER-heterogeneously positive breast cancer

Prof. Lajos Pusztai, Yale School of Medicine

14:15 – 14:45       Spatial predictors of response to neoadjuvant IO therapy-

Dr. Raza Ali, Cancer Research UK, Cambridge Institute

14:45-15:15         Single cell sequencing landscape of breast cancer

Dr. Isaac Chan, Simmons Comprehensive Cancer Centre, University of Texas Southwestern

15:15 – 15:30       Coffee break

ARTIFICIAL INTELLIGENCE AIDED DRUG DEVELOPMENT

Session Chair – Prof. Lajos Pusztai, Yale School of Medicine

15:30 – 16:00       Deep Learning for Drug Discovery: Accelerating Innovation from Data to Molecules

Dr. Mostafa Ahmed, Associate Director, CADD, Atomwise

16:00 – 16:30       Topic: AI tools to accelerate drug development

Dr.Melissa Davis, Head of Computational Biology,Isomorphic labs

16:30– 17:00        Topic: AI-image guided immunotherapy.

Dr. Jeffrey Venstrom, Ambient Bio

Friday 26th September 2025 Lansdowne Suite, Herbert Park Hotel

Registration from 8:30                                               TBC: RCPI external CPD credits                            

SESSION 1: Session Chair – Prof Robert Kerbel, University of Toronto                                                  

09:00 – 09:30       Topic TBC

Prof. Yuval Shaked, Director of the Rappaport-Technion Integrated Cancer Center

09:30 – 10:00        Topic: c-kit ADC / mouse models

Prof. Kabir Khan, UK

10:00 – 10:30        Topic: Prostate/GI NETS cancers

Dr. Iacovos Michael, Sunnybrook Research Institute, University of Toronto.

10:30 – 10:45      Coffee break

SESSION 2: Session Chair – Prof Robert Kerbel, University of Toronto                                      

10:45– 11:15        Topic: VEGF and PD-1 Bi-specific

Dr. Claudia-Nanette Gann, Global Medical Lead, BionTech

11:15 – 11:45       Topic: Targeting the TME in HCC

Dr. Rich Finn, Geffen School of Medicine, UCLA

KEYNOTE PRESENTATION

11:45 – 12:30        Topic: TBC

Dr. Douglas Hanahan, 2025 Winner of the Pezcoller Foundation–American Association for Cancer Research (AACR) International Award for Extraordinary Achievement in Cancer Research, Member of the Royal Society of London and Ludwig Distinguished Scholar, Ludwig Institute for Cancer Research

12:30 – 13:30       Lunch

SESSION 3

Session Chair – Dr. Dimitrios Tryfonopoulos, Medical Oncologist, Saint Savvas Anticancer Hospital, Athens

13:30 – 14:00        Topic: TBC

Immunocore

14:00 – 14:30       Topic: TBC

Dr. Thomas Bogenrieder, CMO, Abalos Therapeutics

14:30 – 15:00        Topic: TBC

Dr. Giuseppe Gullo, Executive Medical Director, Clinical Development, Replimune

15:00– 15:15       Coffee break

SESSION 4

Session Chair   –    Prof William Gallagher, AICRI & University College Dublin

15:15 – 15:45       Banf-1 inhibitor

Dr. Ken O’Byrne, Queensland University of Technology; Princess Alexandra Hospital

15:45 – 16:15        Topic: TBC

Prof. Denis Collins, Dublin City University

16:15 – 16:45       Topic: TBC

Speaker TBC                        

Meeting ends                                                                                           

Similar Posts